For example, oridonin and homoharringtonine exert synergistic effects against t (8; 21) leukaemia through targeting AML1‐ETO and c‐Kit mutation.38 However, the five‐year overall survival in AML patients with AML1‐ETO is still less than 30%. This evidence concerns the gene RUNX1T1 and acute myeloid leukemia.